Bone Biologics (BBLG) Files Patent Application for Bone Regeneration Technology
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
Bone Biologics Files Patent Application for Bone Regeneration Technology
June 27, 2025 7:00 AM EDTBURLINGTON, Mass.--(BUSINESS WIRE)-- Bone Biologics Corporation (Bone Biologics or the Company) (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces the filing of a patent application with the United States Patent and Trademark Office (USPTO) for its novel NELL-1 protein.
The patent application is directed to compositions of rhNELL-1 polypeptide and uses thereof for treating bone conditions.
This patent application marks a major milestone in our mission to bring effective treatments to spine fusion patients, said Jeffrey Frelick, Chief Executive Officer of Bone Biologics.
The patent application, if approved, will strengthen... More
